AbCellera Biologics (ABCL) Corporate presentation summary

Company overview and platform

• Clinical-stage biotech focused on novel antibody medicines, with ~600 employees and operations in Canada and Australia.

• Built a fully integrated antibody drug platform, investing over $500M and 300,000+ sq ft in research and manufacturing.

• Shifted focus in 2023 from partnerships to advancing internal and co-developed programs.

• Maintains $680M in liquidity as of September 30, 2025, supporting strategic execution.

Pipeline and clinical programs

• Two molecules in the clinic (ABCL635, ABCL575), two in IND-enabling activities, and 20+ discovery programs.

• ABCL635 targets NK3R for menopausal vasomotor symptoms, in Phase 2 with readout expected Q3 2026.

• ABCL575 targets OX40L for atopic dermatitis, in Phase 1 with readout anticipated mid-2026.

• ABCL688 (autoimmunity) and ABCL386 (oncology) progressing through IND-enabling studies.

• Plans to nominate at least one additional development candidate for IND-enabling studies in 2026.

Strategic priorities and milestones

• 2025 priorities: clinical trial initiations for ABCL635 and ABCL575, platform investments completed, and new manufacturing site activities started.

• 2026 priorities: topline readouts for ABCL635 and ABCL575, progress on ABCL688 and ABCL386, and new candidate nomination.

• 2027 catalysts include late-stage development for ABCL635, IND submissions, and initiation of new clinical studies.